KALA BIO INC (KALA) Stock Price, Quote, News and Overview
NASDAQ:KALA - Nasdaq - US4831192020 - Common Stock - Currency: USD
KALA Quote, Performance and Key Statistics
NASDAQ:KALA (8/21/2025, 4:27:52 PM)
8.5
+0.16 (+1.92%)
The current stock price of KALA is 8.5 USD. In the past month the price increased by 21.43%. In the past year, price increased by 41.43%.
KALA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.78 | 370.06B | ||
| AMGN | AMGEN INC | 13.56 | 159.03B | ||
| GILD | GILEAD SCIENCES INC | 15.01 | 144.47B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.46 | 102.07B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.11 | 64.58B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 60.96B | ||
| ARGX | ARGENX SE - ADR | 71.6 | 40.62B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.79 | 33.98B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.63B | ||
| INSM | INSMED INC | N/A | 25.16B | ||
| NTRA | NATERA INC | N/A | 22.11B | ||
| BIIB | BIOGEN INC | 8.69 | 20.39B |
Related stock screener links
About KALA
Company Profile
KALA BIO, Inc. is a biopharmaceutical company. The company is headquartered in Arlington, Massachusetts and currently employs 38 full-time employees. The company went IPO on 2017-07-20. The firm is engaged in the research, development, and commercialization of therapies for rare and severe diseases of the eye. The Company’s biologics-based investigational therapies utilize its proprietary mesenchymal stem cell secretome (MSC-S) platform. The Company’s product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biocfactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing, which is an underlying etiology of multiple severe ocular diseases; KPI-014 specific for inherited retinal degenerative diseases. KPI-012 is in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing. The firm is also engaged in the development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases.
Company Info
KALA BIO INC
1167 Massachusetts Avenue
Arlington MASSACHUSETTS 02472 US
CEO: Mark Iwicki
Employees: 38
Phone: 17819965252
KALA BIO INC / KALA FAQ
What is the stock price of KALA BIO INC today?
The current stock price of KALA is 8.5 USD. The price increased by 1.92% in the last trading session.
What is the ticker symbol for KALA BIO INC stock?
The exchange symbol of KALA BIO INC is KALA and it is listed on the Nasdaq exchange.
On which exchange is KALA stock listed?
KALA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for KALA BIO INC stock?
9 analysts have analysed KALA and the average price target is 13.26 USD. This implies a price increase of 56% is expected in the next year compared to the current price of 8.5. Check the KALA BIO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is KALA BIO INC worth?
KALA BIO INC (KALA) has a market capitalization of 54.83M USD. This makes KALA a Micro Cap stock.
How many employees does KALA BIO INC have?
KALA BIO INC (KALA) currently has 38 employees.
What are the support and resistance levels for KALA BIO INC (KALA) stock?
KALA BIO INC (KALA) has a support level at 5.23 and a resistance level at 8.51. Check the full technical report for a detailed analysis of KALA support and resistance levels.
Should I buy KALA BIO INC (KALA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of KALA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of KALA, evaluating the profitability, health, valuation and growth aspects
- KALA BIO INC (KALA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- KALA BIO INC (KALA) Sales and EPS estimates to see what analysts future expectations are.
- KALA BIO INC (KALA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- KALA BIO INC (KALA) Insider and Institutional Ownership to learn about the owners and their transactions.
- KALA BIO INC (KALA) Stock Chart to make your own analysis
- KALA BIO INC (KALA) Latest news and press-releases to stay up to date.
Does KALA BIO INC (KALA) stock pay dividends?
KALA does not pay a dividend.
When does KALA BIO INC (KALA) report earnings?
KALA BIO INC (KALA) will report earnings on 2025-11-10, after the market close.
What is the Price/Earnings (PE) ratio of KALA BIO INC (KALA)?
KALA BIO INC (KALA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-6.6).
What is the Short Interest ratio of KALA BIO INC (KALA) stock?
The outstanding short interest for KALA BIO INC (KALA) is 5.99% of its float. Check the ownership tab for more information on the KALA short interest.
KALA Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to KALA. When comparing the yearly performance of all stocks, KALA is one of the better performing stocks in the market, outperforming 95.88% of all stocks.
KALA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to KALA. KALA has a bad profitability rating. Also its financial health evaluation is rather negative.
KALA Financial Highlights
Over the last trailing twelve months KALA reported a non-GAAP Earnings per Share(EPS) of -6.6. The EPS increased by 52.65% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -73.89% | ||
| ROE | -624.6% | ||
| Debt/Equity | 2.65 |
KALA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 87% to KALA. The Buy consensus is the average rating of analysts ratings from 9 analysts.